You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

 

Online download statistics by month:

Online download statistics by month: July 2021 to November 2024

AbstractFullPdf
Jul 202112371240454
Aug 2021476476146
Sep 2021401401146
Oct 2021336336154
Nov 2021451456135
Dec 2021254258119
Jan 2022250262126
Feb 2022227233169
Mar 2022354378169
Apr 2022272280174
May 2022254301189
Jun 2022254271162
Jul 2022220229120
Aug 202221522288
Sep 202218919490
Oct 202224425293
Nov 2022283285109
Dec 202218318377
Jan 202318418488
Feb 2023317318102
Mar 2023183185101
Apr 202315215394
May 2023225226136
Jun 2023177178117
Jul 202315115183
Aug 202312212463
Sep 202315215761
Oct 202326026079
Nov 202344644980
Dec 202323623672
Jan 2024195197104
Feb 202417517583
Mar 2024267268145
Apr 2024309313138
May 202429329797
Jun 202428228187
Jul 202433534273
Aug 2024230230118
Sep 202419419476
Oct 2024266267105
Nov 202423423972
Total11485116814894